Genetically engineered macrophages persist in solid tumors and locally deliver therapeutic proteins to activate immune responses

BACKGROUND: Though currently approved immunotherapies, including chimeric antigen receptor T cells and checkpoint blockade antibodies, have been successfully used to treat hematological and some solid tumor cancers, many solid tumors remain resistant to these modes of treatment. In solid tumors, the...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:J Immunother Cancer
Egile Nagusiak: Brempelis, Katherine J, Cowan, Courtney M, Kreuser, Shannon A, Labadie, Kevin P, Prieskorn, Brooke M, Lieberman, Nicole A P, Ene, Chibawanye I, Moyes, Kara W, Chinn, Harrison, DeGolier, Kole R, Matsumoto, Lisa R, Daniel, Sara K, Yokoyama, Jason K, Davis, Amira D, Hoglund, Virginia J, Smythe, Kimberly S, Balcaitis, Stephanie D, Jensen, Michael C, Ellenbogen, Richard G, Campbell, Jean S, Pierce, Robert H, Holland, Eric C, Pillarisetty, Venu G, Crane, Courtney A
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: BMJ Publishing Group 2020
Gaiak:
Immune Cell Therapies and Immune Cell Engineering
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC7594542/
https://ncbi.nlm.nih.gov/pubmed/33115946
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/jitc-2020-001356
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak